IPP Bureau
Poly Medicure acquires Italy’s Citieffe Group for Rs. 324 Cr
By IPP Bureau - September 24, 2025
Pharma Manufacturing & Automation Convention 2025 to be held on Oct. 8-9, 2025 in Hyderabad
By IPP Bureau - September 24, 2025
Sessions will cover process mapping, cost optimisation, data-driven decision-making, cybersecurity, and sustainable manufacturing practices
FDA responds to evidence of possible association between autism and acetaminophen use during pregnancy
By IPP Bureau - September 24, 2025
Agency initiates safety label change and notifies physicians of possible link
Teva unveils promising SOLARIS resultsfor Olanzapine LAI
By IPP Bureau - September 23, 2025
No post-injection Delirium/Sedation Syndrome (PDSS) observed through 56 weeks
Akums demonstrates clinical versatility of Lacosamide in epilepsy care
By IPP Bureau - September 23, 2025
Clinical evidence has consistently highlighted lacosamide’s efficacy and safety.
Roche’s subcutaneous lunsumio receives CHMP backing for R/R follicular lymphoma
By IPP Bureau - September 23, 2025
Moderna delivers Canada’s first locally manufactured mRNA vaccines
By IPP Bureau - September 23, 2025
All drug substance for Moderna’s authorized Spikevax (COVID-19 mRNA vaccine) targeting the SARS-CoV-2 LP.8.1 variant is produced at the company’s facility in Laval, Quebec
Roche's Giredestrant combination meets phase III endpoints in advanced breast cancer
By IPP Bureau - September 23, 2025
Importantly, the combination of giredestrant and everolimus was well tolerated
AstraZeneca’s Tezspire recommended for approval in the EU for chronic Rhinosinusitis with nasal polyps
By IPP Bureau - September 23, 2025
Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent
Metropolis Healthcare acquires Ambika Pathology Laboratory
By IPP Bureau - September 22, 2025
Biocon Biologics’ retinal disorder medication Yesafili gets public funding in Canada
By IPP Bureau - September 22, 2025
Yesafili, available in vial and prefilled syringe presentations (2 mg/0.05 mL), was the first biosimilar to Eylea approved by Health Canada
Fermenta to sell environmental solutions business to its subsidiary
By IPP Bureau - September 21, 2025
The entity will undertake the installation, operation, and maintenance of sewage treatment plants
FDA approves Merck's Keytruda injection for cancer therapy
By IPP Bureau - September 21, 2025
Keytruda Qlex is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute
Mankind Pharma collaborates with OpenAI to drive AI-enabled transformation across value chain
By IPP Bureau - September 21, 2025
The goal is to deliver greater value to customers, doctors, and the broader healthcare ecosystem
